Search Within

Raajit Kumar Rampal

Formats
  1. Meeting Abstract (182)
  2. Journal Article (122)
  3. Review (19)
  4. Research Letter (10)
  5. Book Section (2)
  6. Editorial (2)
  7. Guidelines (1)
Groups
  1. Adult Leukemia (338)
  2. Center for Hematologic Malignancies (338)
  3. Department of Medicine (338)
  4. Hematologic Malignancies, Division of (338)
  5. GSK Faculty (135)
  6. Executive Committee, Center for Hematologic Malignancies (131)

More Groups

People
  1. Ross Levine (87)
  2. Omar Abdel-Wahab (64)
  3. Martin Tallman (41)
  4. Eli Diamond (34)
  5. Ahmet Dogan (30)
  6. Minal Patel (29)

More People

Years
  1. 2025 (10)
  2. 2024 (27)
  3. 2023 (42)
  4. 2022 (36)
  5. 2021 (36)
  6. 2020 (26)

More Years

Publications
  1. Blood (139)
  2. Journal of Clinical Oncology (17)
  3. Blood Advances (15)
  4. Clinical Lymphoma, Myeloma and Leukemia (15)
  5. Haematologica (13)
  6. British Journal of Haematology (10)

More Publications

Publishers
  1. American Society of Hematology (155)
  2. Elsevier Inc. (24)
  3. Nature Publishing Group (21)
  4. American Society of Clinical Oncology (17)
  5. Ferrata Storti Foundation (13)
  6. American Association for Cancer Research (12)

More Publishers

Results (338)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • BET inhibitor pelabresib (CPI-0610) combined with ruxolitinib in patients with myelofibrosis - JAK inhibitor-naive or with suboptimal response to ruxolitinib - Preliminary data from the MANIFEST study
    Meeting Abstract

    Mascarenhas, J.; Kremyanskaya, M.; Patriarca, A.; Harrison, C.; Bose, P.; Rampal, R. K.; Palandri, F.; Devos, T.; Passamonti, F.; Hobbs, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Matching-adjusted indirect comparison (MAIC) of pelabresib (CPI-0610) in combination with ruxolitinib vs. JAK inhibitor monotherapy in patients with intermediate or high-risk myelofibrosis
    Meeting Abstract

    Gupta, V.; Mascarenhas, J.; Kremyanskaya, M.; Rampal, R. K.; Talpaz, M.; Kiladjian, J. J.; Vannucchi, A.; Verstovsek, S.; Colak, G.; Dey, D.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of add-on parsaclisib to ruxolitinib therapy in myelofibrosis patients with low versus higher baseline platelet counts: A subgroup analysis of data from a phase 2 study
    Meeting Abstract

    Yacoub, A.; Borate, U.; Rampal, R.; Ali, H.; Wang, E.; Gerds, A.; Hobbs, G.; Kremyanskaya, M.; Winton, E.; O'Connell, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Improvement in individual symptoms and total symptom score (TSS) and matching-adjusted indirect comparison (MAIC) analysis to compare TSS as a continuous endpoint in patients with myelofibrosis treated with pelabresib in combination with ruxolitinib versus janus kinase inhibitor monotherapy
    Meeting Abstract

    Mesa, R.; Kremyanskaya, M.; Patriarca, A.; Gupta, V.; Palandri, F.; Devos, T.; Harrison, C.; Rampal, R. K.; Talpaz, M.; Vannucchi, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Pelabresib (CPI-0610) as add-on to ruxolitinib in myelofibrosis: Durability of response and safety beyond week 24 in the phase 2 MANIFEST study
    Meeting Abstract

    Harrison, C.; Kremyanskaya, M.; Bose, P.; Gupta, V.; Rampal, R. K.; Lambert, J.; Talpaz, M.; Vannucchi, A.; Kuykendall, A.; Kiladjian, J. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Erythroid and megakaryocytic differentiation program in JAK2-mutated acute myeloid leukemia with or without antecedent myeloproliferative neoplasm
    Meeting Abstract

    Liu, Y.; Sethi, S.; Koche, R.; Gao, Q.; Dilip, D.; Glass, J. L.; Galera, P. K.; Persaud, S.; Mishra, T.; Sun, X.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/ essential thrombocythemia myelofibrosis
    Meeting Abstract

    Bewersdorf, J. P.; Verstovsek, S.; Derkach, A.; Masarova, L.; Pemmaraju, N.; Stein, E.; Mauro, M.; Rampal, R. K.; Bose, P.
    Blood (2022)

    Fulltext@MSK | Save
  • Mutational profile of children with myeloproliferative neoplasms
    Meeting Abstract

    Rutherford, K.; Farnoud, N.; Krishnan, A.; Rampal, R. K.; Levine, R. L.; Kucine, N.
    Blood (2022)

    Fulltext@MSK | Save
  • MYLOX-1: An open-label, phase IIa study of the safety, tolerability, pharmacokinetics and pharmacodynamics of oral LOXL2 inhibitor, GB2064, in myelofibrosis
    Meeting Abstract

    Verstovsek, S.; Mascarenhas, J.; Rampal, R. K.; Cilloni, D.; Harrison, C.; Jacoby, B.; Slack, R. J.; Aslanis, V.; Singh, B.; Lindmark, B.
    Blood (2022)

    Fulltext@MSK | Save
  • Molecularly targeted combination therapy for advanced phase myeloproliferative neoplasm: MPN-RC 119
    Meeting Abstract

    Bar-Natan, M.; Mascarenhas, J.; Gerds, A. T.; Mesa, R.; Gupta, V.; Kremyanskaya, M.; Dougherty, M.; Fabris, F.; Johnson, K.; Yu, A.; more...
    Blood (2022)

    Fulltext@MSK | Save